Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
In this retrospective analysis of a large cohort of advanced NSCLC patients treated with pembrolizumab±chemotherapy, OS of hybrid dosed patients was non-inferior to flat dosed patients. OS remained non-inferior after correcting for possible confounding factors. This hybrid regimen resulted in significant savings of pembrolizumab and costs.
Authors
- Egbert F. Smit (ORCID: https://orcid.org/0000-0002-7329-6995)
- Hanieh Abedian Kalkhoran (ORCID: https://orcid.org/0000-0002-6279-6310)
- Willemijn S.M.E. Theelen (ORCID: https://orcid.org/0000-0001-9772-0511)
- Vincent van der Noort (ORCID: https://orcid.org/0000-0002-4910-4535)
- Jeroen J. M. A. Hendrikx (ORCID: https://orcid.org/0000-0001-8201-6599)
- Michiel M. Smeenk (ORCID: https://orcid.org/0009-0004-2083-0930)
Institutions
- Leiden University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- Oncode Institute (NL)
- Haga Hospital (NL)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-010065
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 8.36